Program
ethinyl estradiol, levonorgestrel drug combination
Also written as “Microgynon”, “Microgynon®” and “Ethinyl estradiol/levonorgestrel”.
Its studies are mostly in Tuberculosis · Dyslipidemias · Hematologic Neoplasms · Multiple Sclerosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HRA Pharma | 10 open or running | phase 4since Mar 30, 2012 | Mar 30, 2012 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since Nov 14, 2018 | Nov 14, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2012First study: phase 4 study in Emergency ContraceptionNew to HRA PharmaHRA Pharma · NCT01569113 · 76 enrolled · Netherlands, Sweden, United Kingdom
- Nov 14, 2018Merck KGaA, Darmstadt, Germany’s first study: phase 1 study in Multiple SclerosisNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03745144 · 28 enrolled · Germany, Poland
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03745144Multiple Sclerosis · Germany, Poland | 1 | Completed | Merck KGaA, Darmstadt, Germany | Sep 2, 2022 | 28 |
| NCT01569113Emergency Contraception · Netherlands, Sweden, United Kingdom | 4 | Completed | HRA Pharma | Aug 2012 | 76 |
How it is read
Names in the registry
- “Microgynon”, 3 entries
- “Microgynon®”, 2 entries
- “Ethinyl estradiol/levonorgestrel”, 1 entry
- “ethinyl estradiol/levonorgestrel”, 1 entry
- “Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets”, 1 entry
Conditions, from the studies’ own filings
- Tuberculosis, 1 study
- Dyslipidemias, 1 study
- Hematologic Neoplasms, 1 study
- Multiple Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.